Literature DB >> 23547076

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

Hagop Kantarjian, Wyndham Wilson, Farhad Ravandi, Elihu Estey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23547076     DOI： 10.1200/JCO.2012.48.1465

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal:  Oncologist       Date:  2016-04-18

Review 2.  Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.

Authors:  David Sanford; Farhad Ravandi
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 3.  Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Front Oncol       Date:  2015-12-14       Impact factor: 6.244

4.  The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.

Authors:  Hanne Fredly; Elisabeth Ersvær; Astrid Olsnes Kittang; Galina Tsykunova; Bjørn Tore Gjertsen; Oystein Bruserud
Journal:  Clin Epigenetics       Date:  2013-08-01       Impact factor: 6.551

Review 5.  Decitabine in the treatment of acute myeloid leukemia in elderly patients.

Authors:  Priya Malik; Amanda F Cashen
Journal:  Cancer Manag Res       Date:  2014-02-03       Impact factor: 3.989

6.  Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).

Authors:  Jörg Tomeczkowski; Ansgar Lange; Andreas Güntert; Pushpike Thilakarathne; Joris Diels; Liang Xiu; Peter De Porre; Christoph Tapprich
Journal:  Adv Ther       Date:  2015-09-14       Impact factor: 3.845

Review 7.  Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer.

Authors:  Martina Godel; Giacomo Ortone; Dario Pasquale Anobile; Martina Pasino; Giulio Randazzo; Chiara Riganti; Joanna Kopecka
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.